PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|December 7, 2016
Sanofi, JHL Biotech Launch Biologics Alliance in China
Author(s)Pharmaceutical Technology Editors
JHL Biotech and Sanofi collaborate on the development and commercialization of biological therapeutics in China.
Advertisement
JHL Biotech and Sanofi announced on Dec. 5, 2016 their plans to collaborate on the development and commercialization of biological therapeutics in China. The agreement includes the potential for international expansion.
Sanofi will invest $80 million in JHL shares at $90 per share. Sanofi will also make an upfront payment of $21 million to acquire exclusive rights for the proposed biosimilar of rituximab and options to certain JHL pipeline products. JHL will lead development, registration, and manufacturing activities while Sanofi will lead commercialization efforts in China. JHL is entitled to receive milestones of up to $236 million and sales royalties.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement